Julian Ross

Group Chairman & CEO at Kwivik Therapeutics Inc

Julian Ross led and closed all financing and acquisitions by Kwivik Therapeutics Inc. Invested over $7 million of over $50 million total in company.

He has 30+ years experience in biotech/medtech, high tech, R&D, manufacturing, sales and corporate finance.

He has Public and private company experience includes IPOs and M&A; development of production capabilities, development of sales, distribution and licensing partnerships; and financings with debt and equity (career total in excess of USD $1 Billion).

His other experiences includes a roll-up of network integration, infrastructure engineering and data centre (managed) services companies in the late 90’s. A USD $315 million high yield debt offering in 1996 for Isle of Capri Casinos, Inc. (with Merrill Lynch/Salomon Brothers in lead, plus Deutsche Morgan Grenfell, Nomura Securities) With that financing, Isle of Capri grew from $134 million in revenues to over $1 billion in revenues in less than five years, and was subsequently acquired by Eldorado Resorts (it was recently announced that Eldorado Resorts is acquiring MGM Grand for over USD $8 Billion. Founder investor and director in highly successful, USD $400 million capex gaming & hospitality operation in South Africa.

He is named to the “40 Under 40” by the Dallas Business Journal and his company was selected by the USPTO and the Smithsonian Museum (from thousands of patentholders worldwide) to exhibit at the USPTO’s inaugural Innovation Expo (along with Ford, Caterpillar, Qualcomm and six other innovative companies).

He holds 7 issued patents (with several more pending) and an M.B.A. in Finance from Southern Methodist University, with full ride scholarships from oil & gas giant Shell Petroleum (undergraduate) and the Edwin L. Cox School of Business (post graduate).

Links

Timeline

  • Group Chairman & CEO

    Current role